Tetrous was issued a sixth patent (U.S. Patent No. 12,502,459) related to the EnFix family of demineralized cortical bone fiber implants and their method of manufacture.
The newly-issued patent specifically protects the application of EnFix DBF technology for enthesis reformation. Additionally, issuance of this patent supports the company’s broader strategy to advance biologic augmentation technologies for sports medicine applications.
EnFix DBF technology leverages a proprietary form of demineralized bone fiber engineered to promote osteoinductivity, osteoconductivity and biologic healing while maintaining compatibility with surgical workflows and existing fixation methods. It is designed to complement current mechanical fixation techniques at the bone-to-tendon interface, where biologic integration and early fixation strength are critical determinants of clinical success.
“Securing this patent represents an important milestone for Tetrous as we continue to expand the clinical applications of our EnFix DBF platform,” said Andy Carter, PhD, Cofounder and Chief Technology Officer of Tetrous. “Enthesis Failure Syndrome, or lack of healing at the tendon bone interface, is a common mode of failure in sports medicine repair procedures and this additional patent reflects our focus on clinically relevant innovation.”
Tetrous was issued a sixth patent (U.S. Patent No. 12,502,459) related to the EnFix family of demineralized cortical bone fiber implants and their method of manufacture.
The newly-issued patent specifically protects the application of EnFix DBF technology for enthesis reformation. Additionally, issuance of this patent supports the company's...
Tetrous was issued a sixth patent (U.S. Patent No. 12,502,459) related to the EnFix family of demineralized cortical bone fiber implants and their method of manufacture.
The newly-issued patent specifically protects the application of EnFix DBF technology for enthesis reformation. Additionally, issuance of this patent supports the company’s broader strategy to advance biologic augmentation technologies for sports medicine applications.
EnFix DBF technology leverages a proprietary form of demineralized bone fiber engineered to promote osteoinductivity, osteoconductivity and biologic healing while maintaining compatibility with surgical workflows and existing fixation methods. It is designed to complement current mechanical fixation techniques at the bone-to-tendon interface, where biologic integration and early fixation strength are critical determinants of clinical success.
“Securing this patent represents an important milestone for Tetrous as we continue to expand the clinical applications of our EnFix DBF platform,” said Andy Carter, PhD, Cofounder and Chief Technology Officer of Tetrous. “Enthesis Failure Syndrome, or lack of healing at the tendon bone interface, is a common mode of failure in sports medicine repair procedures and this additional patent reflects our focus on clinically relevant innovation.”
Copy to clipboard 
